3,055 Shares in Stryker Co. (NYSE:SYK) Bought by Sagespring Wealth Partners LLC

Sagespring Wealth Partners LLC purchased a new position in Stryker Co. (NYSE:SYK - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 3,055 shares of the medical technology company's stock, valued at approximately $1,100,000.

Several other institutional investors also recently made changes to their positions in SYK. Kohmann Bosshard Financial Services LLC bought a new position in Stryker in the 4th quarter valued at about $25,000. Rakuten Securities Inc. lifted its stake in Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after buying an additional 68 shares in the last quarter. Centricity Wealth Management LLC purchased a new position in shares of Stryker in the fourth quarter worth approximately $30,000. BankPlus Trust Department purchased a new stake in shares of Stryker in the 4th quarter valued at approximately $33,000. Finally, VSM Wealth Advisory LLC purchased a new position in Stryker during the 4th quarter worth approximately $36,000. 77.09% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on SYK shares. Truist Financial increased their price target on shares of Stryker from $409.00 to $413.00 and gave the stock a "hold" rating in a research report on Thursday, January 30th. Stifel Nicolaus upped their price target on Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a research note on Wednesday, January 29th. Wells Fargo & Company increased their price objective on Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. StockNews.com downgraded Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. Finally, JMP Securities reissued a "market perform" rating on shares of Stryker in a report on Tuesday, February 18th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, Stryker currently has an average rating of "Moderate Buy" and a consensus price target of $423.53.

Stryker Stock Down 0.1 %

Shares of NYSE:SYK traded down $0.21 during trading on Friday, hitting $346.46. 1,349,873 shares of the company's stock traded hands, compared to its average volume of 1,362,954. The company has a market cap of $132.24 billion, a price-to-earnings ratio of 44.65, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average price of $371.83 and a 200-day moving average price of $373.11.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the firm earned $3.46 EPS. As a group, research analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.97%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's dividend payout ratio (DPR) is currently 43.30%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.